Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and PD of Afamelanotide Implants in Healthy Volunteers
NCT03634137Phase 1Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Sep 2009
- Primary completion
- Feb 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Afamelanotide in erythropoietic protoporphyria (EPP) (2 arms), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Change in skin melanin density at 120 days. Started Sep 2009; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT03634137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634137.